PP405 / Pelage Pharma - LARVOL DELTA

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA (clinicaltrials.gov) - P2 | N=78 | Completed | Sponsor: Pelage Pharmaceuticals, Inc. | Active, not recruiting ➔ Completed | Trial primary completion date: Nov 2025 ➔ Jul 2025

Trial completion • Trial primary completion date • Alopecia • Dermatology • Immunology

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA (clinicaltrials.gov) - P2 | N=78 | Active, not recruiting | Sponsor: Pelage Pharmaceuticals, Inc. | N=60 ➔ 78 | Trial completion date: Feb 2025 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Nov 2025

Enrollment change • Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Pelage Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Alopecia • Dermatology • Immunology

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Pelage Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Alopecia • Dermatology • Immunology